Orna Therapeutics

Orna Therapeutics is one of the...

• Unicorn.

Acquisition, funding and merger involving Orna Therapeutics.

• Orna Therapeutics becomes a unicorn with its fundraising of $221 Million. (posted on August 19 2022).

View the org chart displaying its 22 main executives

Most searched biographies at Orna Therapeutics

• Thomas Barnes, Chief Executive Officer
• Brian Goodman, Director
• Daniel Anderson, Director

Popular executive movements at Orna Therapeutics

• Frank Neumann has joined the company as Chief Medical Officer  (posted on April 14 2024).

Create your alert
to follow the executive moves at Orna Therapeutics.

Orna Therapeutics has 2,291 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Lycia Therapeutics has just announced a $107 Million fundraising (posted on May 15 2024).
• Attovia Therapeutics has just announced a $150 Million fundraising (posted on May 14 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on May 13 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Carl Gordon - Director at Adicet Bio
• Vik Bajaj - Director at Interline Therapeutics

Learn more about the Biotechnology industry >

Press releases by Orna Therapeutics

• News & Media - Orna Therapeutics
• News & Media - Orna Therapeutics

Social media about Orna Therapeutics

• Orna Therapeutics on Wikipedia, Google News & Yahoo Finance
• Orna Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Thomas Barnes

Call Orna Therapeutics at +1 857...

View the org chart

Register to receive your alert

Report an error